Straits Times Index
3,307.52 +10.63 (+0.32%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,413.79 +206.66 (+1.14%) FTSE 100
8,172.15 +50.91 (+0.63%) Bitcoin USD
59,777.56 +2,355.07 (+4.10%) CMC Crypto 200
1,285.92 +15.18 (+1.19%)
AZN Jan 2025 57.500 call
| Previous close | 16.35 |
| Open | 20.72 |
| Bid | 20.35 |
| Ask | 23.00 |
| Strike | 57.50 |
| Expiry date | 2025-01-17 |
| Day's range | 20.72 - 20.72 |
| Contract range | N/A |
| Volume | |
| Open interest | 64 |
Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
